Table 2. Univariate and multivariate PFS associations in the Mayo Clinic and public data sets of endometrioid, clear cell, mucinous, or low-grade serous EOC patients.
|
The Mayo Clinic data set (n=131) |
Public rarer histological samples (n=91) |
||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Discovery set (n=66) |
Validation set (n=65) |
Public validation set (n=91) |
|||||||
| HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | |
|
Univariate analysis | |||||||||
| Class-1 vs Class-2 | 0.05 | (0.01–0.24) | 1.2 × 10−4 | 0.07 | (0.01–0.49) | 8.2 × 10−3 | 0.38 | (0.21–0.69) | 1.4 × 10−3 |
| Multivariate analysis |
n=66 |
n=65 |
n=57 |
||||||
| Class-1 vs Class-2 | 0.09 | (0.02–0.42) | 2.4 × 10−3 | 0.08 | (0.009–0.77) | 2.8 × 10−2 | 0.48 | (0.22–1.05) | 6.8 × 10−2 |
| Stage (I vs III and IV) | 0.15 | (0.02–0.95) | 4.4 × 10−2 | 0.35 | (0.093–1.34) | 0.12 | 1.5 × 10−8 | (4.96 × 10−9–4.43 × 10−8) | <2 × 10−16 |
| Stage (II vs III and IV) | 0.35 | (0.11–1.17) | 0.09 | 0.80 | (0.23–2.78) | 0.73 | 1.41 | (0.42–4.74) | 0.58 |
| Debulking statusa | 1.10 | (0.42–2.90) | 0.84 | 3.44 | (1.35–8.76) | 9.4 × 10−3 | 3.29 | (1.76–6.16) | 2.0 × 10−4 |
Abbreviations: CI=confidence interval; EOC=epithelial ovarian cancer; HR=hazards ratio; PFS=progression-free survival.
a
Mayo: other vs having no macroscopic disease; Public: suboptimal vs optimal.